| __timestamp | BioCryst Pharmaceuticals, Inc. | Biogen Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 1171036000 |
| Thursday, January 1, 2015 | 1896000 | 1240400000 |
| Friday, January 1, 2016 | 2699000 | 1478700000 |
| Sunday, January 1, 2017 | 1702000 | 1630000000 |
| Monday, January 1, 2018 | 471000 | 1816300000 |
| Tuesday, January 1, 2019 | 4101000 | 1955400000 |
| Wednesday, January 1, 2020 | 1676000 | 1805200000 |
| Friday, January 1, 2021 | 7264000 | 2109700000 |
| Saturday, January 1, 2022 | 6594000 | 2278300000 |
| Sunday, January 1, 2023 | 4661000 | 2533400000 |
| Monday, January 1, 2024 | 0 |
Unleashing insights
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue for Biogen Inc. and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Biogen Inc. consistently demonstrated a robust cost structure, with its cost of revenue peaking at approximately $2.5 billion in 2023, marking a 116% increase from 2014. In contrast, BioCryst Pharmaceuticals, Inc. showed a more volatile pattern, with costs ranging from $122,000 in 2014 to a high of $7.3 million in 2021. Despite the disparity in scale, BioCryst's cost efficiency improved significantly, with a 3,700% increase from 2014 to 2021. This comparison highlights the diverse strategies employed by these companies in managing their operational expenses, offering valuable insights into their financial health and strategic priorities.
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Biogen Inc.
Cost of Revenue Trends: Sanofi vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Zoetis Inc. and Biogen Inc.
Cost Insights: Breaking Down Biogen Inc. and Intra-Cellular Therapies, Inc.'s Expenses
Cost of Revenue Comparison: Biogen Inc. vs Xenon Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Biogen Inc. and HUTCHMED (China) Limited
R&D Spending Showdown: Biogen Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Vericel Corporation vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.